The book launch of Annual Report on Development of China Blood Transfusion Industry (2022), compiled by CSBT, was held through online live broadcast on the afternoon of September 23. Members attended the book launch were GONG Jiwu, Chief Creator and Editor; REN Wenwu, Director of City and Green Development Branch of Social Sciences Literature Publishing House; GENG Hongwu, Executive Editor; HU Wei and LUO Qun，Deputy Chief Editors.

This blue book, jointly written by domestic experts, discusses the development of blood transfusion industry in 2021 and shows professional experience, independent views, and expectations.

The book consists of eight parts:

Part Ⅰ General Report  provides an analysis and prospects on the development of China’s blood collection and supply industry in 2021, including blood collection and supply, clinical blood transfusion, the release of standard consensus and academic education exchange activities.

Part Ⅱ Provincial-level Report  provides reports of blood collection and supply in three provinces and one region in the northwest of China.

Part Ⅲ Municipal-level Report  provides reports of blood collection and supply from five cities in Zhejiang Province, Yunnan Province, Hunan Province, Hebei Province, Liaoning Province, respectively and one district in Beijing.

Part Ⅳ Clinical Transfusion Report  provides reports regarding clinical blood transfusion management from five cities in Heilongjiang Province, Jilin Province, Liaoning Province, Shanxi Province and Inner Mongolia Autonomous Region, respectively.

Part Ⅴ Monographic Reports  provides nine reports on specific topics including: the development of blood group gene detection technology in China; clinical transfusion management information system; the automation progress of blood screening; monitoring of quality indicators in blood screening laboratories; maternal immunohematology management; reagents for transfusion compatibility test; red cell antibody identification and the criteria for antibody screening cell; the application of HTLV-1/2 antibody screening among Chinese blood donors.

Part Ⅵ Case Report  provides five reports, including: model construction of blood supply and demand for emergent blood supply; clinical application of therapeutic plasma exchange in Shanghai; solutions to pediatric clinical blood transfusion problems; transfusion therapy for postpartum hemorrhage; the application of cloud platform for plasma aphaeresis establishment in Zhejiang Province.

Part Ⅶ Biography Report of Professor SHI Mingzhen, a pioneer of immunohematology in China .

Part Ⅷ Industry Chronicle  Chronicle of blood service in 2021.

Reported by the CSBT Secretariat

Translated by ZHANG Rui

Reviewed by MA Ling, JIANG Nizhen